Higher Binding Affinity and In Vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab

Reslizumab and mepolizumab are recently approved monoclonal antibodies for the treatment of severe (uncontrolled) eosinophilic asthma. Both are effective in neutralizing the function of interleukin-5 (IL-5). This study is the first to compare the binding affinity and in vitro potency of both antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Liddament, Mark, Husten, Jean, Estephan, Tanya, Laine, David, Mabon, David, Pukac, Laurie, Lyons, Jacquelyn, Clarke, Adam W., Doyle, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340799/
https://www.ncbi.nlm.nih.gov/pubmed/30661320
http://dx.doi.org/10.4168/aair.2019.11.2.291

Ejemplares similares

Ejemplares similares